Validation and calibration of a computer simulation model of pediatric HIV infection

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Ciaranello, Andrea L ^a,b   Morris, Bethany L ^a   Walensky, Rochelle P ^a,b,c   Weinstein, Milton C ^d   Ayaya, Samuel ^e   Doherty, Kathleen ^a   Leroy, Valeriane ^f   Hou, Taige ^a   Desmonde, Sophie ^f   Lu, Zhigang ^a   Noubary, Farzad ^a   Patel, Kunjal ^d   Ramirez Avila, Lynn ^a,g,h   Losina, Elena ^a,b,c,i   Seage III, George R ^d   Freedberg, Kenneth A ^a,c,d,i  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MOI UNIVERSITY   (Kenya)

^f INSERM   (France)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFRICA; ARTICLE; CALIBRATION; CD4 LYMPHOCYTE COUNT; CHILD; CHILDHOOD MORTALITY; COMPUTER SIMULATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; OPPORTUNISTIC INFECTION; SURVIVAL RATE; VALIDATION STUDY;

ADOLESCENT; AFRICA; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL;

EID: 84892632399     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083389     Document Type: Article

References (58)

1. Prendergast A, Cotton M, Gibb DM (2008) When should antiretroviral therapy be started for HIV-infected infants in resource-limited settings? Futures - Journal of HIV Therapy 2: 201-208.
2. Ciaranello AL, Park J, Ramirez-Avila L, Freedberg KA, Walensky RP et al. (2011) Early infant HIV-1 diagnosis programs in resource-limited settings: opportunities for improved outcomes and more cost-effective interventions. BMC Medicine 9: 59.
3. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Recommendations for a public health approach.
4. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ et al. (2001) The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 344: 824-831.
5. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, et al. (2006) Cost-effectiveness of HIV treatment in resource-poor settings - the case of Côte d'Ivoire. N Engl J Med 355: 1141-1153.
6. Walensky RP, Wolf LL, Wood R, Fofana MO, Freedberg KA et al. (2009) When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 151: 157-166. doi: 10.7326/0003-4819-151-3-200908040-00138. PubMed: 19620143.
7. Johri M, Ako-Arrey D (2011) The cost-effectiveness of preventing mother-to-child transmission of HIV in low- and middle-income countries: systematic review.Cost Eff Resour Alloc 9: 3. doi:10.1186/1478-7547-9-3. PubMed: 21306625.
8. Shah M, Johns B, Abimiku A, Walker DG (2011) Cost-effectiveness of new WHO recommendations for prevention of mother-to-child transmission of HIV in a resource-limited setting. AIDS 25: 1093-1102. doi:10.1097/QAD.0b013e32834670b9. PubMed: 21505317.
9. Orlando S, Marazzi MC, Mancinelli S, Liotta G, Ceffa S et al. (2010) Cost- effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-Project Malawi. J Acquir Immune Defic Syndr 55: 631-634. doi:10.1097/QAI.0b013e3181f9f9f5. PubMed: 21934555.
10. Robberstad B, Evjen-Olsen B (2010) Preventing mother to child transmission of HIV with highly active antiretroviral treatment in Tanzania - a prospective cost-effectiveness study. J Acquir Immune Defic Syndr 55: 397-403. doi:10.1097/QAI.0b013e3181eef4d3. PubMed: 20739897.
11. Ciaranello AL, Perez F, Engelsmann B, Walensky RP, Mushavi A, et al. (2013) Cost-effectiveness of World Health Organization 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe. Clin Infect dis 56: 430-446.
12. Ciaranello A, Perez F, Keatinge J, Park J, Engelsmann B et al. (2012) What will it take to eliminate pediatric HIV? Reaching "virtual elimination" targets for prevention of mother-to-child HIV transmission (PMTCT) in Zimbabwe. PLOS Medicine 9: e1001156.
13. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB (1996) Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 276: 1253-1258.
14. Hunink MGM, Glasziou PP, Siegel JE, Weeks JC, Pliskin JS et al. (2003). Decision making in health and medicine: integrating evidence and values. Cambridge: Cambridge University Press.
15. Schneider K, Puthanakit T, Kerr S, Law MG, Cooper DA, et al. (2011) Economic evaluation of monitoring virologic responses to antiretroviral therapy in HIV-infected children in resource-limited settings. AIDS 25: 1143-1151.
16. Ryan M, Griffin S, Chitah B, Walker AS, Mulenga V et al. (2008) The cost- effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia.AIDS 22: 749-757. doi:10.1097/QAD.0b013e3282f43519. PubMed: 18356605.
17. Menzies NA, Homsy J, Chang Pitter JY, Pitter C, Mermin J et al. (2009) Cost- effectiveness of routine rapid human immunodeficiency virus antibody testing before DNA-PCR testing for early diagnosis of infants in resource-limited settings. Pediatr Infect Dis J 28: 819-825. doi:10.1097/INF.0b013e3181a3954b. PubMed: 20050391.
18. Ciaranello AL, Lockman S, Freedberg KA, Hughes M, Chu J et al. (2011) First- line antiretroviral therapy after single-dose nevirapine exposure in South Africa: A cost-effectiveness analysis of the OCTANE trial. AIDS 25: 479-492. doi:10.1097/QAD.0b013e3283428cbe. PubMed: 21293199.
19. Rydzak CE, Cotich KL, Sax PE, Hsu HE, Wang B et al. (2010) Assessing the performance of a computer-based policy model of HIV and AIDS. PLOS ONE 5: e12647. doi:10.1371/journal.pone.0012647. PubMed: 20844741.
20. Yazdanpanah Y, Losina E, Anglaret X, Goldie SJ, Walensky RP, et al. (2005) Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS 19: 1299-1308.
21. Paltiel AD, Weinstein MC, Kimmel AD, Seage GR 3rd, Losina E, et al. (2005) Expanded screening for HIV in the United States - an analysis of cost-effectiveness. N Engl J Med 352: 586-595.
22. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC et al. (2005) Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 41: 1316-1323. doi:10.1086/496984. PubMed: 16206108.
23. Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS (2009) Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics 27: 13.
24. Goldhaber-Fiebert JD, Stout NK, Goldie SJ (2010) Empirically Evaluating Decision-Analytic Models. Value in Health 13: 8-13. doi:10.1111/j.1524-4733. 2010.00698.x
25. Eddy DM, Hollingworth W, Caro JJ, Tsevat J, McDonald KM, et al. (2012) Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force - 7. Value Health 15: 843-850.
26. Brinkhof MW, Dabis F, Myer L, Bangsberg DR, Boulle A et al. (2008) Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 86: 559-567. doi:10.2471/BLT.07.044248. PubMed: 18670668.
27. National Institute of Allergy and Infectious Disease (2012) International Epidemiologic Databases to Evaluate AIDS. In: . pp. IeDEA. Home Page
28. Ciaranello A, Lu Z, Ayaya S, Losina S, Musick B et al. (2011). Incidence of WHO Stage 3 (WHO3) and 4 (WHO4) events and tuberculosis (TB) in untreated HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases for the Evaluation of AIDS) East African regional analysis; Rome, Italy.
29. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ (2002) Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol 156: 761-773.
30. Vanni T, Karnon J, Madan J, White RG, Edmunds WJ et al. (2011) Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics 29: 35-49. doi:10.2165/11584600-000000000-00000. PubMed: 21142277.
31. Ciaranello AL, Perez F, Maruva M, Chu J, Engelsmann B et al. (2011) WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: Modeling clinical outcomes in infants and mothers. PLOS ONE 6: e20224. doi:10.1371/journal.pone.0020224. PubMed: 21655097.
32. Sheon AR, Fox HE, Rich KC, Stratton P, Diaz C et al. (1996) The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. Journal of Women's Health 5: 69-78. doi:10.1089/jwh.1996.5.69.
33. National Technical Information Service (2010) Women and Infants Transmission Study (WITS) public database, final release, 1990-2006 (issued December 10, 2010) Alexandria, VA.
34. Foca M, Moye J, Chu C, Matthews Y, Rich K et al. (2006) Gender differences in lymphocyte populations, plasma HIV RNA levels, and disease progression in a cohort of children born to women infected with HIV. Pediatrics 118: 146-155. doi:10.1542/peds.2005-0294. PubMed: 16818560.
35. Marston M, Becquet R, Zaba B, Moulton LH, Gray G et al. (2011) Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan. Africa - Int J Epidemiol 40: 385-396. doi:10.1093/ije/dyq255.
36. Becquet R, Marston M, Dabis F, Moulton LH, Gray G et al. (2012) Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PLOS ONE 7: e28510. doi:10.1371/journal.pone.0028510. PubMed: 22383946.
37. UNAIDS Child Survival Working Group (2010) Survival of children HIV-infected perinatally and through breastfeeding: a pooled analysis of individual data from resource-constrained settings. (UNAIDS report on survival of HIV infected children in Africa, final report). Geneva, Switzerland: UNAIDS.
38. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 1236-1243.
39. United Nations (2009) World Population Prospects: The 2008 Revision. In: Department of Economic and Social Affairs PD, editor. New York
40. Egger M, Boulle A (2008) Population effect of scaling up ART in resource-poor settings. Lancet 371: 1558-1559. doi:10.1016/S0140-6736(08)60669- 8. PubMed: 18468529.
41. McIntyre JA, Martinson N, Gray GE, Hopley M, Kimura T et al. (2005). Addition of short course Combivir (CBV) to single dose Viramune (sdNVP) for the prevention of mother to child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI- resistant virus. Rio de Janeiro.
42. Laird NM, Ware JH (1982) Random-effects models for longitudinal data.Biometrics 38: 963-974. doi:10.2307/2529876. PubMed: 7168798.
43. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V et al. (2008) Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 22: 1333-1343. doi:10.1097/QAD. 0b013e32830437df. PubMed: 18580613.
44. Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C et al. (2007) High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS 21: 1253-1261. doi:10.1097/QAD.0b013e3281a3bec2. PubMed: 17545701.
45. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J et al. (2008) Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 359: 2233-2244.
46. Spira R, Lepage P, Msellati P, Van De Perre P, Leroy V et al. (1999) Natural history of human immunodeficiency virus type 1 infection in children: a five- year prospective study in Rwanda. Mother-to-Child HIV-1 Transmission Study Group. Pediatrics 104: e56. doi:10.1542/peds.104.5.e56. PubMed: 10545582.
47. Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, et al. (2006) Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr 42: 637-645
48. Chearskul S, Chotpitayasunondh T, Simonds RJ, Wanprapar N, Waranawat N et al. (2002) Survival, disease manifestations, and early predictors of disease progression among children with perinatal human immunodeficiency virus infection in Thailand. Pediatrics 110: e25. doi: 10.1542/peds.110.2.e25. PubMed: 12165624.
49. Graham SM, Mtitimila EI, Kamanga HS, Walsh AL, Hart CA, et al. (2000) Clinical presentation and outcome of pneumocystis carinii pneumonia in Malawian children. Lancet 355: 369-373.
50. Adhikari M, Kauchali S, Moodley A (2006) Clinical profile and morbidity pattern of infants born to HIV infected mothers in Durban South Africa.Indian Pediatr 43: 804-808. PubMed: 17033119.
51. Ferrand RA, Luethy R, Bwakura F, Mujuru H, Miller RF et al. (2007) HIV infection presenting in older children and adolescents: a case series from Harare, Zimbabwe. Clin Infect Dis 44: 874-878. doi:10.1086/511873. PubMed: 17304463.
52. Desmonde S, Coffie P, Aka E, Amani-Bosse C, Messou E et al. (2011) Severe morbidity and mortality in untreated HIV-infected children in a paediatric care programme in Abidjan, Cote d'Ivoire, 2004-2009. BMC Infect Dis 11: 182. doi:10.1186/1471-2334-11-182. PubMed: 21699728.
53. Hussey GD, Reijnhart RM, Sebens AM, Burgess J, Schaaf S, et al. (1998) Survival of children in Cape Town known to be vertically infected with HIV-1. S Afr Med J 88: 554-558.
54. Cross Continents Collaboration for Kids. (2008) (3Cs4kids) Analysis and Writing Committee (2008) Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 22: 97-105. doi:10.1097/01.aids.0000302262.51286.a5. PubMed: 18090397.
55. Bagenda D, Nassali A, Kalyesubula I, Sherman B, Drotar D et al. (2006) Health, neurologic, and cognitive status of HIV-infected, long-surviving, and antiretroviral-naive Ugandan children. Pediatrics 117: 729-740. doi:10.1542/peds.2004-2699. PubMed: 16510653.
56. Munyagwa M, Baisley K, Levin J, Brian M, Grosskurth H, et al. (2012) Mortality of HIV-infected and uninfected children in a longitudinal cohort in rural south-west Uganda during 8 years of follow-up. Trop Med Int Health 17: 836-843.
57. Fryback DG, Stout NK, Rosenberg MA, Trentham-Dietz A, Kuruchittham V (2006) et al. Wisconsin Breast Cancer Epidemiology Simulation Model. JNCI Monographs 36: 11.
58. Spiegelhalter DJ, Best NG (2003) Bayesian approaches to multiple sources of evidence and uncertainty in complex cost-effectiveness modelling. Stat Med 22: 3687-3709. doi:10.1002/sim.1586. PubMed: 14652869.